Table of Contents
| << Previous Issue | Sep 2012 (Vol: 2012, Issue: 9) | Next Issue >> |
- Section: Distribution & Marketing
-
Pfizer Signs Long-Term Generics Collaboration with Mylan in Japan
- Section: Joint Venture
-
AstraZeneca Forms Joint Venture with Wuxi AppTec to Accelerate Biologics Development in China
- Section: Licensing
-
Allergan Strengthens its Ophthalmology Pipeline with US$1.5 B Alliance with Molecular Partners
-
Genmab Signs US$1.1 B Daratumumab Licence Agreement with Janssen Biotech
-
Merck Serono Licenses Global Rights to Symphogen’s Sym004 Cancer Antibody Mixture
-
Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST
-
Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib
- Section: Mergers & Acquisitions
-
Hospira Boosts Antibiotic Business with Acquisition of Orchid’s API Facilities
-
Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout
-
Sunovion Strengthens its Respiratory Portfolio by Acquiring Elevation Pharmaceuticals
-
Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option
- Section: Research & Development
-
Silence Therapeutics Collaborates with MiReven to Evaluate Delivery of miR-7 Mimetic
-
Sanofi Collaborates with Oncodesign to Develop Inhibitors of Challenging Kinase Targets
-
SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC
RSS